The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 7 May 2026•Updated 8 May 2026•

1 min read

Charles River Q1 Results Beat Estimates as Analysts Raise Price Targets

Key Facts

1Charles River Laboratories was downgraded to 'Sell' following a 57% rally in share price over the past year.

2The company reported a 1.5% decline in organic revenue alongside margin compression during the first quarter.

3The company maintained its 2026 EPS guidance of $10.80–$11.30 despite looming regulatory and AI risks.

Charles River Laboratories reported robust first-quarter results, with adjusted EPS of $2.06 beating the consensus estimate of $1.94. Quarterly sales reached $995.830 million, exceeding analyst expectations despite previous concerns regarding organic revenue trends. In response to the beat, Evercore ISI Group and Barclays raised their price targets for the stock while maintaining positive ratings, signaling renewed confidence. This strong performance comes as investors evaluate the company's ability to defend margins amidst a complex operating environment. However, the market continues to weigh these positive earnings against long-term structural risks and valuation levels. The latest data represents a significant pivot from the earlier narrative of organic decline and cautious sentiment.

27 days ago

Version History

Version 127 days ago

What changed: Updated the story to reflect Q1 earnings and revenue beats, and price target increases by Evercore ISI and Barclays.